Abstract
Sotalol is a class III anti-arrhythmic agent with beta receptor blocking properties. Intravenous (IV) sotalol may be useful to treat refractory atrial and ventricular arrhythmias. A report on the efficacy and safety of IV sotalol in an infant on extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT), who developed refractory ventricular arrhythmias following surgery for congenital heart disease. A 10-day old infant with severe pulmonary valve stenosis underwent surgical pulmonary valvectomy and enlargement of the main pulmonary artery. Post-operatively, the patient developed hemodynamically significant accelerated idioventricular rhythm which was not responsive to a combination of amiodarone, lidocaine, and procainamide leading to 2 cardiac arrest events and placement on ECMO. The amiodarone infusion was uptitrated to 20 mcg/kg/min, but episodes of the hemodynamically compromising arrhythmia continued. Amiodarone was discontinued and IV sotalol was initiated at 42 mg/m2/day, divided to 3 doses, and administered every 8 h, which completely suppressed the arrhythmia. The initial sotalol dose was calculated based on a daily dose of 90 mg/m2 and reduced by an age-related factor as recommended by the FDA approved prescribing information. Subsequently, acute kidney injury requiring CRRT developed. The patient remained on IV sotalol for 3 weeks and then transitioned to oral sotalol. The oral dose was increased to 44 mg/m2/day (3.5 mg every 8 h) to account for the difference in bioavailability between the IV and oral formulations. Serial sotalol levels during IV and PO therapy remained therapeutic on ECMO and CRRT. The patient maintained normal sinus rhythm on sotalol without adverse events. IV sotalol in the setting of ECMO and CRRT was safe and effective in controlling refractory hemodynamically compromising accelerated idioventricular rhythm unresponsive to amiodarone.
References
Shekar K, Fraser JF, Smith MT, Roberts JA (2012) Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 27:741.e9–818.e9
Milsap RL, Jusko WJ (1994) Pharmacokinetics in the infant. Environ Health Perspect 102:107–110
Sotalol hydrochloride injection for intravenous use [package insert] (1992) Academic Pharmaceuticals, Lake Bluff
Altathera Pharmaceuticals (2019) Dosing for pediatric patients under 2 years of age. https://www.altathera.com/dosing-calculator/. Accessed 12 May 2019
Taketomo CK, Hodding JH, Kraus DM (2017) Pediatric & neonatal dosage handbook, 24th edn. Lexi-comp, Inc., Hudson
Valdes SO, Landstrom AP, Schneider AE et al (2018) Intravenous sotalol for the management of postoperative junctional ectopic tachycardia. Heart Rhythm Case Rep 4:375–377
Kim H, Wolff J, Dalal A, Van Hare GF, Avari Silva JN (2017) Use of intravenous sotalol in newborns with supraventricular tachycardia. Heart Rhythm Case Rep 3:332–335
Aljohani OA, Perry JC, Williams MR (2018) Intravenous sotalol for conversion of atrial flutter in infants. Heart Rhythm Case Rep 4:117–120
Li X, Zhang Y, Liu H, Jiang H, Ge H, Zhang Y (2017) Efficacy of intravenous sotalol for treatment of incessant tachyarrhythmias in children. Am J Cardiol 119:1366–1370
Kannan R, Yabek SM, Garson A, Garson A Jr, Miller S, McVey P, Singh BN (1987) Amiodarone efficacy in a young population: relationship to serum amiodarone and desethylamiodarone levels. Am Heart J 114:283–287
Kendrick JG, Macready JJ, Kissoon N (2006) Amiodarone treatment of junctional ectopic tachycardia in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother 40:1872–1875
Watt K, Li J, Benjamin D, Cohn-Wolkowiez M (2011) Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. J Cardiovasc Pharmacol 58:126–132
Allegaert K, van den Anker JN, Naulaers G, de Hoon J (2007) Determinants of drug metabolism in early neonatal life. Curr Clin Pharmacol 2:223–229
Laer S, Elshoff JP, Meibohm B et al (2005) Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 46:1322–1330
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jacobson, J.L., Somberg, J.C. & Nguyen, H.H. Intravenous Sotalol for the Treatment of Ventricular Dysrhythmias in an Infant on Extracorporeal Membrane Oxygenation. Pediatr Cardiol 41, 418–422 (2020). https://doi.org/10.1007/s00246-019-02225-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-019-02225-w